ArticlePharmacoEconomics2026
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data.
Adam Irving et al.PubMed ↗Publisher ↗
No numbers read from the abstract.